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Triple-negative breast cancers show
large variation in sensitivity to the
chemotherapeutic agent cisplatin that
cannot be explained by defects in DNA
repair. Heijink et al. conducted a systems-
level analysis of cisplatin-induced signal
transduction and reveal that signaling
dynamics can be used to predict cisplatin
sensitivity of TNBC models.
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Triple-negative breast cancers (TNBCs) display great
diversity in cisplatin sensitivity that cannot be ex-
plained solely by cancer-associated DNA repair de-
fects. Differential activation of the DNA damage
response (DDR) to cisplatin has been proposed to
underlie the observed differential sensitivity, but it
has not been investigated systematically. Systems-
level analysis—using quantitative time-resolved
signaling data and phenotypic responses, in combi-
nation with mathematical modeling—identifies that
the activation status of cell-cycle checkpoints deter-
mines cisplatin sensitivity in TNBC cell lines. Specif-
ically, inactivation of the cell-cycle checkpoint regu-
lator MK2 or G3BP2 sensitizes cisplatin-resistant
TNBC cell lines to cisplatin. Dynamic signaling data
of five cell cycle-related signals predicts cisplatin
sensitivity of TNBC cell lines. We provide a time-
resolved map of cisplatin-induced signaling that un-
covers determinants of chemo-sensitivity, under-
scores the impact of cell-cycle checkpoints on
cisplatin sensitivity, and offers starting points to opti-
mize treatment efficacy.
INTRODUCTION
In standard care, breast cancers are subtyped based on the
expression of the estrogen and progesterone receptors (ER
and PR, respectively) and human epidermal growth factor recep-
tor-2 (HER2). These receptors are oncogenic drivers and rele-
vant drug targets. Breast cancers lacking expression of ER,
PR, and HER2 are called triple-negative breast cancers (TNBCs);
they do not benefit from anti-hormonal or anti-HER2 treatments,
and they account for 15%–20% of invasive breast cancers
(Foulkes et al., 2010). Although patients with TNBC can initially
respond to chemotherapy, they have worse overall prognosis
compared with other breast cancer subtypes. Unfortunately,
TNBCs lack clear targetable driver oncogenes, constituting anCell Re
This is an open access article under the CC BY-Nunmet need to improve the therapeutic options for these
patients.
Apart from chemotherapy, no treatments are proven to be
effective for this patient group. Among genotoxic chemothera-
peutic agents, platinum-based chemotherapeutics, such as
cisplatin, are potential treatment options for TNBC patients and
predominantly showed favorable responses in TNBCswith under-
lyingBRCA1/2mutations (Byrski et al., 2010; Cardoso et al., 2017;
Rouzier et al., 2005; Silver et al., 2010). When tested in vitro using
panels of TNBC models, platinum-containing agents appeared
effective, although the observed sensitivity varied significantly
(Lehmann et al., 2011). TNBC is a heterogeneous breast cancer
subtype, so identifyingmolecular features of TNBC that are critical
for cisplatin sensitivity will likely be necessary for these drugs to be
used effectively. At the molecular level, cisplatin introduces both
intra- and inter-strand DNA crosslinks (ICLs), which stall replica-
tion forks and are therefore especially toxic in proliferating cells
(Siddik, 2002). ICL-induced stalled replication forks activate the
DNA damage response (DDR) and initiate DNA repair through
multiple DNA repair pathways, including homologous recombina-
tion (HR), nucleotide excision repair (NER), and Fanconi anemia
(FA) (Kim and D’Andrea, 2012; Shuck et al., 2008). The ability of
cells to repair DNA crosslinks is considered a critical determinant
for the cytotoxic effect of cisplatin treatment (Bhattacharyya et al.,
2000; Kim and D’Andrea, 2012). Consequently, mutations and/or
reduced expression of HR and FA genes are robustly linked to
sensitivity of platinum-based chemotherapeutics (Taniguchi
et al., 2003). Nevertheless, cisplatin sensitivity is not always asso-
ciatedwith defective HR, NER, or FA. An important challenge is to
unravel which other factors determine the efficacy of cisplatin
treatment and to investigate whether such factors could be
used as targets to potentiate chemo-sensitivity of TNBC cells.
The complexity of the DDRmakes it challenging to predict how
cancers will respond to DNA-damaging chemotherapy. For
instance, it is becoming clear that the DDR does not function as
an isolated linear signaling pathway but rather is a large signaling
network that interconnects canonical DDR pathways with addi-
tional pro-growth and pro-death signaling pathways (Ciccia and
Elledge, 2010; Costelloe et al., 2006; Jackson and Bartek,
2009). In addition, signaling through the DDR occurs non-linearly
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Figure 1. Heterogeneous Responses to Cisplatin in TNBC Cell Lines
(A) Indicated TNBC cell lines were treated with cisplatin for 72 h. Methyl thiazol tetrazolium (MTT) conversion was measured, and growth rate-adjusted drug
responses (GR metrics) were plotted. Error bars indicate SEM of at least three independent experiments with three technical replicates each. MDA-MB-231 and
MDA-MB-157 are called MB-231 and MB-157, respectively.
(B) Indicated TNBC cell lines were irradiated (10 Gy) or left untreated and analyzed for RAD51 foci 3 h later. Scale bar represents 10 mM.
(C) Indicated TNBC cell lines were treated with mitomycin C (MMC, 50 ng/mL) for 24 h. FANCD2 ubiquitination was assessed by western blotting.
(D) Characteristics of all 9 tested TNBC cell lines are listed. GR50 values for cisplatin were calculated from averages of three independent experiments. TP53,
BRCA1, and BRCA2 mutation status was obtained from the Cosmic database.
See also Figure S1.adaptation and rewiring following stimulation (Lee et al., 2012).
Differential activation and wiring of the DDR in response to
cisplatin has beenproposed to underlie the differences in cisplatin
sensitivity (Brozovic et al., 2009; Wang et al., 2012). Therefore, it
has proven difficult to predict chemo-sensitivity based on the
presence or activity of DDR components, which are typically
measured at a single static moment after cisplatin treatment.
Detailed understanding of how signaling dynamics fluctuate
over time and how molecular signals are integrated may be
necessary to better understand chemo-sensitivity in TNBCs.
To meet this challenge, we performed a systems-level analysis
in cisplatin-sensitive and cisplatin-resistant TNBC cell lines. We
collected quantitative time-resolved signaling data on the activa-
tion status of several key signaling proteins, together with pheno-
typicdata reportingapoptoticandcell-cycle regulatory responses.
These data were integrated using statistical modeling, revealing
that cisplatin-induced changes in cell-cycle signaling molecules
determine cisplatin-induced initiation of cell death and that these
profiles could be useful in predicting cisplatin responses.
RESULTS
Large Variation in Cisplatin Sensitivity in Human TNBC
Cell Lines
We assembled a panel of well-described human TNBC cell lines
and measured cellular viability after 72 h of continuous cisplatin2346 Cell Reports 28, 2345–2357, August 27, 2019treatment. To control for potential confounding effects of differ-
ences in growth rates, we calculated growth rate inhibition met-
rics (GR values) (Hafner et al., 2016). Large variations in sensi-
tivity were observed among the nine cell lines, with GR50s
ranging from 2.2 mM in HCC1937 to 61 mM in MDA-MB-231 (Fig-
ure 1A). The increased cisplatin sensitivity of two TNBC cell lines,
SUM149PT and HCC1937, could be rationalized based on
defective HR because of BRCA1 mutations. For other cell lines,
even within the same molecular TNBC subtype, differences in
cisplatin sensitivity could not be explained by underlying
BRCA1/2 mutations.
To better comprehend the complexity of the cellular response
to cisplatin, we aimed to identify factors other than DNA repair-
related elements, which determine cisplatin sensitivity. We
therefore measured multiple DDR-related signaling nodes in hu-
man TNBC cell line models with different levels of sensitivity to
cisplatin but similar DNA repair status.
We selected two cisplatin-sensitive TNBC cell lines (HCC38
and BT549) and two cisplatin-resistant TNBC cell lines (MDA-
MB-231 andMDA-MB-157) of the sameClaudin-low breast can-
cer subtype. To test whether the differential cisplatin sensitivity
was caused by defective HR, NER, or FA pathways, we analyzed
RAD51 foci formation after irradiation as a measure of HR profi-
ciency (Figure 1B), assessed FANCD2 ubiquitination after mito-
mycin C (MMC) treatment as measure of FA proficiency (Fig-
ure 1C), and screened for mutations in NER and mismatch
repair (MMR) genes. In all four selected cell lines, RAD51 foci
were clearly induced after irradiation, confirming HR proficiency
(Figures 1B and 1D). In addition, all four cell lines showed mono-
ubiquitinated FANCD2 upon MMC treatment (Figure 1C), illus-
trating FA pathway functionality (Figures 1C and 1D). We did
not find pathogenic mutations in NER or MMR pathway compo-
nents or genomic scars associated with MMR deficiency (Fig-
ure S1), which are described as contributing to repair of
cisplatin-induced DNA lesions. Thus, the selected Claudin-low
TNBC cell lines show differences in cisplatin sensitivity that do
not appear to be caused by deficiencies in DNA repair.
Creation of a Signal-Response Dataset for Cisplatin
Sensitivity
To identify which DDR-related signals determine cisplatin sensi-
tivity, we aimed to determine the relationship between changes
in DDR-related signaling proteins and cellular responses to
cisplatin. We measured the levels or activation states of 22
signaling proteins that comprise the DDR, cell-cycle machinery,
and/or apoptotic cell death pathways and six phenotypic re-
sponses (Figure 2A). Each signal was quantified at 11 time points
following exposure to 2 or 20 mM cisplatin, resulting in 44 mea-
surements of each signal protein (green) with corresponding
loading controls (red) (Figure 2B, upper panel). Fold changes
(FLDs) across all cell lines and cisplatin concentrations were
quantified (Figures 2B, bottom panel, and 2C). To identify the po-
tential relationship between signaling dynamics and differential
sensitivity to cisplatin, we concomitantly measured phenotypes
related to cisplatin treatment, including induction ofDNAdamage,
changes in cell-cycle progression, and cell death (Figure 2D).
These responses were quantified at 12 time points between
0 and 120 h after cisplatin exposure using flow cytometry (Figures
2D and 2E). All signaling and phenotypic responsemeasurements
were performed in biological and experimental duplicates in
HCC38, BT549, MDA-MB-157, and MDA-MB-231 cells, yielding
a dataset of 3,872 molecular signals measurements and 1,044
cellular response measurements (Figures 2C and 2E; Table S1).
The addition of cisplatin caused clear dose-dependent in-
creases in the percentage of sub-G1 cells and in the magnitude
ofmanymolecular signals (Figures 2C and 2E). For example, after
exposure to 20 mM cisplatin, phosphorylation of H2AX rose to a
maximum fold increase of 55, while with 2 mM cisplatin, this level
increased 22-fold. Baseline protein levels or activation states of
most individual signals were poorly correlated with sub-G1 levels
after 120 h of cisplatin treatment (Figure S2), indicating that sensi-
tivity to cisplatin is poorly predicted by overall DDR activity states
before drug exposure. In addition, the activation patterns of the
molecular signals did not show clear dose-dependent changes.
The activation patterns of signals differed strongly between cell
lines, without clear distinctions between cisplatin-sensitive and
cisplatin-resistant cell lines. Thus, clear dose-dependent changes
could be observed in themagnitude ofmost signals, but the dura-
tion and pattern of activation differed strongly between cell lines.
Statistical Modeling Using Partial Least-Squares
Regression (PLSR)
Tomore rigorously analyze the DDR signaling data after cisplatin
treatment, we used PLSR (Geladi and Kowalski, 1986). PLSRfunctions by identifying a reduced set of metavariables (or prin-
cipal components [PCs]) that maximize co-variation between
molecular signaling input variables and cellular response output
responses (Figure S3; Janes and Yaffe, 2006). The first PC cap-
tures the greatest amount of information within the data. Addi-
tional PCs are identified iteratively to maximally capture residual
variance until additional PCs cease to capture meaningful data
(relative to the technical error of measurements). This approach
can be used to simplify complex data and to uncover hidden as-
sociations between signals and phenotypic outcomes that may
be missed visually.
Prior quantitative analysis of signaling has revealed that many
networks respond to changes in levels of protein activation,
rather than to absolute activation levels (Gaudet et al., 2005;
Janes et al., 2008). These dynamic features can be obscured
by large differences between cell lines in the overall magnitude
of signal activation. To highlight signaling dynamics in our
models, we derived six metavariables-metrics from our time-
staggered signaling dataset. These signaling dynamic metrics
were (1) FLD, (2) slope between adjacent time points (SLP), (3)
maximum slope (SMX), (4) dynamic range (DYN), (5) total activity
(area under the curve, AUC), and (6) average level of activity
(AVE). In addition, time-dependent measurements were divided
into three time frames—early, ranging from 0 to 2 h; middle,
spanning 2 to 12 h; and late, ranging from 12 to 24 h—to capture
specific time regimes in which fluctuation in signal dynamics
best correlated with cellular response. In total, 132 metrics
were composed, based on 22 molecular signals and 6 metavari-
ables. Using this approach, signaling dynamics were included in
the input variables (signals), while output variables (responses)
were encoded using uncoupled time points. Each response var-
iable was represented by the average value calculated for each
time frame.
We initially explored these data by building amodel composed
of the data from all four cell lines. The resulting model reduced
the dataset into four PCs (Figure S3B). Altogether, these four
PCs explained 60% of the overall variance (R2), and predicted
29% of the variation, using a cross-validation scheme (Q2) (Fig-
ure S3B). These low model-fitness parameters reflected that the
underlying data were not well captured in a single model. Based
on this observation, we speculated that the signaling proteins
were used in a fundamentally different manner in cisplatin-sensi-
tive and cisplatin-resistant cell lines. Thus, we next separated the
data to build two separatemodels: one for cisplatin-sensitive cell
lines and one for cisplatin-resistant cell lines. Our partial least-
squares (PLS) model of cisplatin-sensitive cell lines HCC38
and BT549 captured 81.6% of the co-variance between signals
and responses with the first two PCs (Figure S3C). Likewise,
81.4% of the co-variance in the data of the cisplatin-resistant
cell lines MDA-MB-231 and MDA-MB-157 was explained by
the first two PCs of the cisplatin-resistant model (Figure S3D).
In both cases, we observed significant improvements in model
prediction accuracy, with Q2 parameters increasing to more
than 80% for both models. In both cisplatin-sensitive and
cisplatin-resistance models, PC1 largely captured the variation
associated with the different time regimens (Figure 3A), whereas
PC2 captured cell line-specific variance (Figure 3A). To deter-
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Figure 2. A Systems-Level Signal-Response Dataset following Cisplatin
(A) An expanded DNA damage signaling-response network, including canonical components of the DDR, growth, and stress response pathways. Signals in-
tegrated in the model are green, and responses are blue.
(legend continued on next page)
2348 Cell Reports 28, 2345–2357, August 27, 2019
cisplatin-sensitive and cisplatin-resistance models reflect simi-
larities in the biological responses within these cells, we created
models from all random pairs of cell lines. These other models
produced substantially reduced fitting parameters, with R2 and
Q2 values of 30% and 10%, respectively (Figure S3E), sug-
gesting that model-fitness improvements emerged because of
similar biological responses within cisplatin-sensitive and
cisplatin-resistant cells.
To examine the quality of our models, we used jack knife-
based cross-validation to compare each measured cellular
response in isolationwith the responses predicted by ourmodels
(Gong, 1986). Both models were particularly accurate in predict-
ing the sub-G1 apoptotic response, cell-cycle state, and extent
of gH2AX phosphorylation following cisplatin treatment. The cor-
relations between measured responses and those predicted by
our model were above 0.97 (Figures 3B, S3F, and S3G). Thus,
the combination of signaling metrics and responses was
adequate to build two well-fit models that could predict cellular
responses, including at sub-G1 levels, in response to cisplatin.
Because model fitness required sensitive and resistant cells to
be modeled separately, the underlying differences between
cisplatin-sensitive and cisplatin-resistant cells were not likely
to be different levels of activation within similarly functioning net-
works but instead were likely to be caused by signaling through
fundamentally different networks.
PLS Model Identifies Determinants of Cisplatin
Sensitivity
To better understand how specific signal transduction proteins
influence the responses to cisplatin, we projected the loading
vectors for each model feature into the PC vector space (Janes
and Yaffe, 2006). Vector loadings report the contribution of each
signal to the variation captured by a specific PC. This information
can be used to highlight critical features that differentiate be-
tween cisplatin responses in sensitive and resistant cells. In
both models, we observed a strong anti-correlation between
sub-G1 and G1, which was captured by PC1 in both instances
(Figure 3C). Thus, signals that contribute strongly to PC1 are
likely to be important for cisplatin sensitivity in these cells. The
vector loading plot revealed many signals and signaling features
that are strongly co-variant with sub-G1 cells, suggesting that
multiple signaling features, rather than a single signal, are critical
for predicting cisplatin sensitivity in TNBC cells.
Because both models could accurately predict cell death, we
next wished to determine whether specific signal proteins
contributed to this differential accumulation of sub-G1 in(B) Protein abundance and activation levels were analyzed bywestern blotting usin
to actin, and plotted as FLD compared with the lowest measurement across all
western blot shown on top. Mean values ± SD of two experiments are shown.
(C) The complete signaling dataset for four TNBC cell lines following 2 or 20 mM
duplicate experiments. Grayscale reflects signal strength. Background color indic
increase in yellow, and sustained decrease in blue, as explained in the STAR Meth
(D) Measurements of response data. DNA content, percentages of mitotic cells, an
fluorescence-activated cell sorting (FACS) plot showing cell-cycle profiles based
measured by sub-G1 were quantified. Middle panel: percentage of mitotic cells as
in G1 cells was quantified as phospho-H2AX mean fluorescence intensity in 2n c
(E) The complete response dataset colored as in (C).
See also Figure S2 and Table S1.response to cisplatin in our models. Our strategy was to identify
the signals that were the most differentially weighted in sensitive
versus resistant cells, because these signals might underlie the
difference in cisplatin sensitivity in TNBC cell lines. A particularly
interesting example was MK2, an inflammation-related and cell-
cycle checkpoint kinase, whose role in the DDR remains unclear.
In the model of cisplatin-sensitive cells, pMK2 showed positive
co-variance with subsequent emergence of sub-G1 cells, sug-
gesting that this protein contributes to cisplatin-induced cell
death (Figure 3D). In contrast, in the cisplatin-resistant model,
dynamic MK2-related metrics were negatively correlated with
sub-G1, suggesting that activation of MK2 promotes cell death
in sensitive cells but paradoxically inhibits cell death in resistant
cells.
To test these model-generated predictions, cisplatin-sensitive
(BT549) and cisplatin-insensitive (MDA-MB-231) cell lines were
transduced with short hairpin RNAs (shRNAs) targeting MK2
(Figure S4A). Consistent with our model-based predictions,
knockdown of MK2 reduced cisplatin sensitivity in cisplatin-sen-
sitive BT549 cells (Figure 3E, left panel). The cisplatin-resistant
cell line MDA-MB-231 showed contrasting results. Consistent
with the model’s paradoxical prediction that MK2 activation pre-
vents cell death in cisplatin-resistant cell lines, knockdown of
MK2 resulted in enhanced cisplatin sensitivity in MDA-MB-231
cells (Figure 3E, right panel).
Among the signals that showed the largest differences in PC1
scores between the sensitive and the resistant PLS models,
many were linked to cell-cycle regulation (Figures 3D and
S4B). Whereas other signal classifications showed a similar dis-
tribution of PC1 scores in the sensitive and the resistant models,
PC1 scores of cell cycle-related signals showed a differential
distribution (Figures 3D and S4C). These data underscore that
cisplatin sensitivity is linked to the ability of cancer cells to acti-
vate cell-cycle checkpoint signaling, which is in linewith a role for
cell-cycle checkpoints in preventing transmission of DNA lesions
to daughter cells to protect genome integrity.
Cisplatin-Induced Changes in Cell-Cycle Progression
and Cell Death in TNBC Cell Lines
To test whether altered cell-cycle checkpoint activation could
differentiate between the selected cisplatin-sensitive and the
selected cisplatin-resistant TNBC cell lines, we monitored cell-
cycle dynamics at several time points after treatment with
cisplatin (Figure 4A). Both insensitive cell lines showed transient
S/G2 cell-cycle arrest, after which proliferation was resumed
(Figures 4A and 4B). In contrast, cisplatin-sensitive cell linesg two-color infrared detection (top). Signal intensity was quantified, normalized
cell lines and treatments. The signaling time course plot is presented from the
cisplatin treatment. Each box represents an 11-point time course of biological
ates signaling profile: sustained increase in green, late increase in red, transient
ods section. Numbers below each plot report the maximum FLD on the y axis.
d level of DNA damage were measured by flow cytometry. Left panel: example
on DNA content. Percentage of cells in G1, S, and G2 phases and cell death
measured by phospho-histone H3 positivity. Right panel: level of DNA damage
ells.
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Figure 3. PLSR Correctly Predicts Sub-G1 from Molecular Signals Activated by Cisplatin
(A) PLSR analysis of covariation between molecular signals and cellular responses. Score plots represent the signaling response of each TNBC cell line at a
specified time, as indicated by the colors and symbols in the legend. Scores are plotted for the sensitive and resistant PLS models.
(B) Correlation between measured sub-G1 (flow cytometry, y axis) and model-predicted sub-G1 (x axis).
(C) PLS loadings plotted for signals and responses and colored by signaling class.
(D) PC1 loading scores of the dynamic signaling metrics (FLD, fold change; DYN, dynamic range; SMX, maximum slope; SLP, slope) are plotted. Loading scores
of the four dynamicmetrics of pMK2 and their average are shown in the upper panel. Loading scores of the dynamic metrics of all cell cycle-related signals (PLK1,
Aurora-A, CyclinB1, CDC25C, and CDC25A) and their averages are shown in the bottom panel.
(E) Cisplatin sensitivity of BT549 and MDA-MB-231 cell lines, transduced with indicated shRNAs measured by MTT conversion. Inset bar graphs depict MTT
conversion upon treatment with 7.5 or 15 mM cisplatin of BT549 and MDA-MB-231, respectively.
Error bars indicate SEM of three independent experiments. The p values were calculated using two-tailed Student’s t test. ****p < 0.0001. See also Figures S3
and S4.ceased cell-cycle progression at theG2 stage and remainedwith
4n DNA for the remainder of the experiment (Figures 4A and 4B).
Similar results were obtained when synchronized cell cultures
were treated with cisplatin (Figures S5A and S5B).
When TNBC cell lines were treated with high-dose cisplatin
(20 mM), both sensitive and resistant cell lines entered prolonged
cell-cycle arrest (Figures 4A and 4B). In line with their high sensi-
tivity to cisplatin, BT549 and HCC38 displayed clear induction of
apoptosis, as judged by the proportion of cells with sub-G1 DNA
content, in contrast to MDA-MB-231 and MDA-MB-157 cells
(Figure 4C). Thus, in line with our modeling data, cisplatin-sensi-
tive and cisplatin-resistant TNBC cell lines show different cell-
cycle distributions in response to cisplatin.2350 Cell Reports 28, 2345–2357, August 27, 2019To explore whether the cell-cycle arrest kinetics were related
to dynamics of DNA damage resolution, TNBC cell lines were
transduced with GFP-tagged MDC1, which binds gH2AX and
therefore serves as a marker for DNA breaks (Stucki et al.,
2005). Live cell imaging revealed that cisplatin-resistant cell lines
accumulated DNA damage in response to cisplatin treatment, as
evidenced by GFP-MDC1 foci, but only entered mitosis when
DNA damage foci were resolved (Figures 4D and 4E). In contrast,
cisplatin-sensitive cell lines often enteredmitosis in the presence
of GFP-MDC1 foci. This was particularly pronounced in HCC38
cells, which entered mitosis with very high levels of DNA damage
that remained visible even after cells exited mitosis (Figure 4D
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Figure 4. Cisplatin-Induced Changes in Cell-Cycle Progression and Cell Death in TNBC Cell Lines
(A–C) Quantitative cell-cycle analysis. Cells were treated with 2 or 20 mM cisplatin, and cell-cycle profiles were analyzed at indicated time points. (A) Repre-
sentative cell-cycle profiles of MDA-MB-157 (red) and BT549 (blue) cells after treatment with 2 or 20 mM cisplatin. (B) Quantification of G1 cells from two in-
dependent experiments. Error bars indicate SEM. (C) Quantification of sub-G1-cells from two independent experiments. Error bars indicate SEM.
(D and E) TNBC cell lines stably expressing GFP-MDC1 were treated with cisplatin (2 mM) for 24 h before time-lapse imaging, and cell fate was assessed. (D)
Representative cells are shown, with time point M1 showing the last frame before mitosis, M1 indicating the onset of mitosis, M2 denoting mitotic exit, andM+1
presenting the first time frame after cytokinesis. Scale bar represents 17 mM. (E) Quantification of MDC1 foci before mitosis (open circles) and after mitosis (filled
circles). At least 10 cells have been analyzed per condition. Error bars indicate SEM.
(F) Gene Ontology (GO) pathway analysis of differentially expressed genes (DEGs). MDA-MB-231, MDA-MB-157, HCC38, and BT549 cells were left untreated or
were treated with 2 mM cisplatin for 72 h. For each cell line, DEGs were classified based on GO enrichment analysis. GO terms that appeared in both cisplatin-
sensitive and cisplatin-insensitive cell lines are indicated. Upregulated GO terms are yellow, and downregulatedGO terms are blue. Color intensity is based on the
p value.
(G) Overlap between DEGs of cisplatin-sensitive and cisplatin-resistant TNBC cell lines. Genes with a FLDR 1.75 in sensitive cell lines, as well as in resistant cell
lines, are red.
See also Figure S5 and Table S2.
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cells are unable to properly repair DNA breaks before mitotic en-
try, possibly caused by slippage through prolonged DNA dam-
age-induced G2/M cell-cycle arrest.
Our prior data suggested that differences in DDR and cell-cy-
cle checkpoint signaling may account for the observed differ-
ences in cisplatin sensitivity. We next explored cisplatin-induced
gene expression changes to reiterate this notion and potentially
highlight signals that may contribute to the observed differences
in drug sensitivity. To investigate this, we analyzed changes in
gene expression 72 h after low-dose cisplatin (2 mM) in both sen-
sitive and resistant TNBC cell lines (Figure S5C). Gene Ontology
(GO) pathway analysis of differentially expressed genes (DEGs)
revealed a strong enrichment for genes involved in cell-cycle
regulation, DNA repair, mRNA processing, and apoptosis (Fig-
ure 4F), although the DEGs showed limited overlap between
cell lines (Figure 4G; Table S2). In line with our cell-cycle progres-
sion data, gene expression analysis showed decreased expres-
sion of G2/M cell-cycle pathway components and lowered levels
of DNA repair genes in cisplatin-resistant cell lines after 72 h of
treatment. In contrast, cisplatin-sensitive cell lines consistently
showed upregulated expression of G2/M cell-cycle pathways
(Figure 4F). These data suggest that cell-cycle progression or
the ability to install damage-induced cell-cycle checkpoint arrest
determines the cellular response to cisplatin. However, the
limited numbers of DEGs and the lack of significant overlap of
altered genes between cell lines suggested that cisplatin sensi-
tivity is not predominantly transcriptionally controlled but rather
is driven by post-translational modifications.
G3BP2 Depletion Promotes Cell-Cycle Arrest in
Cisplatin-Resistant Cell Lines
Among the genes that revealed contrasting regulation between
cisplatin-sensitive versus cisplatin-resistant TNBC cell lines,
three genes were identified, G3BP2, HMMR, and NEK2, that
were previously remotely linked to DNA damage but were not
associated to cisplatin response (Figure 4G; Fletcher et al.,
2004; Isabelle et al., 2012; Sohr and Engeland, 2008). We
measured their levels after cisplatin treatment in our selected
TNBC cell lines (Figure S6A) and added these data to our previ-
ously collected dataset. PLSRmodeling using this expanded da-
taset resulted in improved predictive models, with Q2 parame-
ters of 91% and 92% for the sensitive and resistant models,
respectively (Figure S6B).
To identify the minimal subset of signaling features that are
required to accurately predict cisplatin sensitivity, we iteratively
removed signals, beginning with those contributing the least to
model fitness (lowest variable importance in projection [VIP]
score) (Gaudet et al., 2005). For PLS models of either sensitive
or resistant cells, we found that the full predictive capacity of
ourmodels required only the 4 or 6most informativemetrics (Fig-
ures 5A and S6C). In parallel, we performed this analysis in the
inverse order, iteratively removing signals starting with the high-
est VIP score. These models were also resilient to this type of
perturbation, because the full predictive capacity of the model
was unchanged even when the top 60 most informative metrics
were eliminated (Figure 5B). Thus, accurate predictions could be
generated using models that contained either the most or the
least informative signals, albeit with a substantially larger number2352 Cell Reports 28, 2345–2357, August 27, 2019of signals required when the least informative signals are used.
Altogether, these data highlight that predictive information is
not rare in signaling data but rather is redundantly encoded
throughout the signaling network.
The metrics with the highest predictive accuracy differed be-
tween the sensitive and the resistant models. Signaling metrics
of G3BP2 were critical for model predictive accuracy in the sen-
sitivemodel, while thesewere absent within the top VIP scores of
the resistant model (Figure 5A). In addition, the dynamic metrics
of G3BP2 had the opposite PC1 score in sensitive versus resis-
tant models (Figure 5C). These data indicate that G3BP2 pro-
motes cell death in sensitive cells but paradoxically inhibits cell
death in resistant cells. To test this prediction, cisplatin-sensitive
(BT549) and cisplatin-insensitive (MDA-MB-231) cell lines were
transduced with shRNAs targeting G3BP2 (Figure S6D). Consis-
tent with our modeling-based predictions in cisplatin-insensitive
TNBC cells, depletion of G3BP2 sensitized MDA-MB-231 cells
to cisplatin (Figure 5D). However, knockdown of G3BP2 did
not significantly alter cisplatin sensitivity in BT549 cells
(Figure 5D).
To examine whether G3BP2 knockdown changed the
behavior of MDA-MB-231 to resemble other aspects of the
behavior observed for cisplatin-sensitive cell lines, we analyzed
cell-cycle distribution after cisplatin treatment. To this end,
MDA-MB-231 cells were transduced with doxycycline-inducible
shRNAs targeting G3BP2. Although control cell lines were only
transiently arrested in G2, G3BP2-depleted cells maintained
G2 arrest (Figures 5E and 5F). In line with this observation,
G3BP2 knockdown cells accumulated more cisplatin-induced
DNA damage when compared with control cells (Figure 5G).
Although MDA-MB-231 cells are described as displaying
mesenchymal features (Lombaerts et al., 2006), their
morphology changed upon G3BP2 knockdown into a mobile
phenotype with extensive protrusions (Figure S6E). To test
whether knockdown of G3BP2 had influence on the epithelial-
mesenchymal transition (EMT) in MDA-MB-231 cells, we
analyzed the abundance of different EMT-related factors.
Although control MDA-MB-231 cells showed expression of the
mesenchymal markers Fibronectin and ZEB1, knockdown of
G3BP2 resulted in a decrease in their expression (Figure S6F).
Conversely, the expression of the epithelial marker E-cadherin
increased after knockdown of G3BP2 (Figure S6F).
PLS Models Trained on Cisplatin-Sensitive and
Cisplatin-Resistant Cells Accurately Predict Cisplatin
Sensitivity in a Panel of TNBC Cells
To validate whether cisplatin-induced signaling dynamics of
pMK2, RPA, and G3BP2 can predict cisplatin sensitivity beyond
the model training set of four TNBC cell lines, we measured the
abundance of these three signals, together with the levels of
BCL-xL and pKAP1—the two highest scoring signals in our orig-
inal models—following cisplatin treatment in three untested
TNBC cell lines (MDA-MB-468, HCC1806, and HCC1143).
Although these cell lines were all relatively sensitive to cisplatin,
they displayed a significant range in GR50 (MDA-MB-468,
0.7 mM; HCC1806, 3.8 mM; and HCC1143, 14.7 mM) (Figure 6A).
Based on our PLS modeling, we anticipated that signaling met-
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Figure 5. Robustness of PLSR Models, and Validation of G3BP2 as a Determinant of Cisplatin Sensitivity
(A and B) The minimal number of signaling metrics required for predicting sub-G1 was calculated by iteratively removing metrics. The fraction of G3BP2-related
metrics among metrics with the highest VIP scores is indicated in pie charts. (A) Metrics were eliminated sequentially from the models of cisplatin-sensitive cell
lines (left panel) or cisplatin-resistant cell lines (right panel) based on the relative magnitude of their coefficients in the model, from highest to lowest VIP score. (B)
Metrics were sequentially eliminated from the model of cisplatin-sensitive cell lines from lowest to highest VIP score.
(C) PC1 loading scores of the dynamic signaling metrics of G3BP2 and their average are plotted for the sensitive and resistant models individually.
(legend continued on next page)
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predict cisplatin sensitivity. To test this notion, we generated a
new PLS model with data from the original dataset (i.e., four
TNBC cell lines treated with 20 mM) in combination with data
from the additional three cell lines. The score plot for this com-
bined dataset showed that PC1 separated all cell lines based
on their cisplatin sensitivity, including the three additional cell
lines (Figure 6B). The least-sensitive cell line of the validation
panel, HCC1143, was located between the resistant and the
sensitive cell lines of the original model, while the projection of
HCC1806 and MDA-MB-468 was similar to that in the
cisplatin-sensitive cell lines (Figure 6B). We used this minimal
model to predict the sub-G1 percentage for the validation panel
in response to cisplatin. Sub-G1was accurately predicted for the
newly included cell lines (R2 = 0.849) (Figure 6C). Thus, using only
the five most important signals for distinguishing cisplatin-sensi-
tive from cisplatin-insensitive cell lines, PLS modeling success-
fully captured levels of cisplatin sensitivity. Altogether, our data
highlight a small compendium of signals—including RPA,
pMK2, and G3BP2—that are used differently in the context of
cisplatin-sensitive and cisplatin-resistant TNBC cells to promote
the observed differences in drug sensitivity.
DISCUSSION
In this study, we describe a systematic time-resolved approach
to identify molecular signals that can distinguish cisplatin-sensi-
tive from cisplatin-resistant TNBC cell lines. We found that cell-
cycle checkpoint factors appeared to determine cisplatin sensi-
tivity in TNBC cell line models that do not harbor obvious DNA
repair defects. These findings are in line with earlier observations
that expression levels of theWEE1 and CHK1 kinases are related
to cisplatin sensitivity (Pouliot et al., 2012) and that targeting of
cell-cycle checkpoints, including ATR, CHK1, and WEE1, can
be used to sensitize cancer cells to cisplatin (Gadhikar et al.,
2013; Hirai et al., 2009; Perez et al., 2006; Reaper et al., 2011;
Sangster-Guity et al., 2011).
At the cellular level, we observed that both sensitive and resis-
tant cell lines engage cisplatin-induced S/G2 cell-cycle arrest.
However, whereas resistant cell lines recommence cell-cycle
progression, cisplatin-sensitive models did not. Our data indi-
cate that cisplatin-induced changes in signaling, rather than
static states of signaling molecules before treatment, are impor-
tant in determining cell fate.
Our finding that differences in treatment-induced signaling dy-
namics determine phenotypic outcomes is in apparent contrast
to the finding that kinase-effector signaling is stable across
models from the same lineage (Miller-Jensen et al., 2007). This
discrepancy could be caused by the different origins of the cell
line models. TNBCs are highly genomically instable (Curtis(D) MDA-MB-231 and BT549 cells were transduced with indicated shRNAs and M
MTT conversion upon treatment with 7.5 mM cisplatin. sh#1 and sh#2 refer to sh
dependent experiments. The p values were calculated using two-tailed Student’
(E and F) MDA-MB-231 cells with doxycycline-inducible shRNAs targeting lucife
cycle profiles were determined by flow cytometry (E). Means and SDs of percen
(G) gH2AX levels after 2 mMcisplatin treatment for 72 h.MDA-MB-231 cells expres
anti-gH2AX antibody and propidium iodide. gH2AX levels and DNA content were
See also Figure S6.
2354 Cell Reports 28, 2345–2357, August 27, 2019et al., 2012), and individual TNBCs may have evolved contrarily
in their ability to deal with DNA lesions, possibly influenced by
the various baseline levels of endogenous DNA lesions. In addi-
tion, previous quantitative modeling studies of the DNA damage
signaling in single models demonstrated context dependence,
especially involving mitogen-activated protein kinase (MAPK)
signaling (Lee et al., 2012; Tentner et al., 2012). The stability of
signal processing across models may be different for inflamma-
tory stress versus genotoxic agents (Miller-Jensen et al., 2007).
Changes in G3BP2 expression after cisplatin treatment were
identified as one of the signals that correlated strongly with cell
death following cisplatin exposure. Previously, G3BP2 was
described as playing a role in stress granule formation (Gupta
et al., 2017) and was found to be involved in Twist-induced
EMT (Wei et al., 2015). In line with these reports, G3BP2 deple-
tion in the cisplatin-resistant cell line MDA-MB-231 reduced
mesenchymal cell morphology, resulted in prolonged cisplatin-
induced G2 cell-cycle arrest, and led to increased sensitivity to
cisplatin (Wei et al., 2015). These results underscore a role for
mesenchymal transition in reduced chemo-sensitivity. Our data
suggest that such a mesenchymal transition is versatile and
that targeting G3BP2 in mesenchymal-like cisplatin-resistant
TNBC cells may increase chemo-sensitivity.
In the context of defective p53, cancer cells were previously
shown to increasingly depend on p38MAPK/MK2 for proper
cell-cycle checkpoint control and survival after DNA damage
(Manke et al., 2005). Specifically, inactivation of MK2 was re-
ported to abrogate cell-cycle checkpoint responses and to
sensitize tumor cells to cisplatin in vitro and in vivo (Dreaden
et al., 2018; Morandell et al., 2013; Reinhardt et al., 2010). Other
studies demonstrated MK2 to be involved in DNA damage-
induced replication fork stalling (Ko¨pper et al., 2013). In the latter
case, MK2 knockdown rescued gemcitabine-induced replica-
tion stalling and increased cell survival. Our data also show
opposite roles for MK2 in dictating cell survival after DNA dam-
age. Knockdown of MK2 resulted in increased cisplatin sensi-
tivity in the cisplatin-resistant cell line MDA-MB-231 but reduced
cisplatin-sensitive of BT549 cells. The impact ofMK2modulation
on cisplatin sensitivity was surprising, because we observed
only limited changes in pMK2 levels upon cisplatin treatment.
These data underscore the utility of our modeling approach in
identifying key regulators of signaling outcome and suggest a
context-dependent requirement for MK2 in checkpoint re-
sponses. Although modulation of MK2 activity resulted in the
predicted opposite effects on cisplatin sensitivity, the effect
sizes were relatively modest. This may again reflect the redun-
dant wiring of DNA damage-induced cell-cycle checkpoints, as
well as pro-apoptotic signaling, in which the effects of MK2 inac-
tivation are partially buffered by parallel signaling axes. FurtherTT conversion after cisplatin treatment was measured. Inset bar graphs depict
G3BP2#1 and shG3BP2#2, respectively. Error bars indicate SEM of three in-
s t test. ***p < 0.001.
rase or G3BP2 were treated with 2 mM cisplatin. At indicated time points, cell-
tages of G2 cells from three independent experiments are plotted (F).
sing inducible shRNAs against luciferase or G3BP2were fixed and stained with






































































Figure 6. Validation of PLS Model-Generated Predictions in Additional TNBC Cell Lines
(A) Cisplatin sensitivity of the validation cell lines (colored) compared with the original four cell lines (gray). After cells were treated with cisplatin for 72 h, MTT
conversion was measured and growth rate-adjusted drug responses (GR metrics) were plotted. Averages and error bars of at least three replicates are shown.
(B) Score plot of the general PLSmodel comprehended with signaling (pMK2, RPA, G3BP2, pKAP1, and BCL-xL) and response data of additional TNBC cell lines
(MDA-MB-468, HCC1806, and HCC1143).
(C) Correlation plot between measured sub-G1 by flow cytometry (y axis), and cross-validated predictions of sub-G1 (x axis) by the PLS model.research is warranted to uncover which tumors may benefit from
combined treatment with platinum-containing chemotherapeu-
tics and MK2 inhibitors.
In finding predictive biomarkers for chemo-response, the
status of a signaling molecule is typically assessed in treat-
ment-naive tumors. We measured signaling flux at various
time points in response to cisplatin treatment and found
signaling dynamics to be of key importance in predicting
cellular response to cisplatin. These results underscore that
steady-state levels of signaling molecules in untreated tumor
cells or clinical tumor material may have low predictive value,
and in an ideal scenario, samples before and shortly after start
of treatment should be analyzed. Moreover, the notion that
predictive information is redundantly encoded in our models
implies that a limited set of signaling features may be suffi-
cient to probe signaling dynamics in response to cisplatin
treatment.
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Antibodies
Anti-RAD51 GeneTex Cat# GTX70230; RRID:AB_372856
Anti-FANCD2 Santa Cruz Cat# sc-20022; RRID:AB_2278211
Anti-G3BP2 Bethyl Cat# A302-040A, RRID:AB_1576545
Anti-MAPKAPK-2, phospho (Thr334) Cell Signaling Cat# 3041, RRID:AB_330726
Anti-RPA32/RPA2 Abcam Cat# ab2175, RRID:AB_302873
Anti-B-actin MP Biomedicals Cat# 08691001, RRID:AB_2335127
Anti-Histone H2A.X, phospho (Ser139) Cell Signaling Cat# 9718, RRID:AB_2118009
Anti-Histone H3, phospho (Ser10) Cell Signaling Cat# 9706, RRID:AB_331748
Anti-CDC25C Cell Signaling Cat# 4688, RRID:AB_560956
Anti-Phospho-Chk1 (Ser345) (133D3) Cell Signaling Cat# 2348, RRID:AB_331212
Anti-Phospho-Chk2 (Thr68) (C13C1) Cell Signaling Cat# 2197, RRID:AB_2080501
Anti-ATR, phospho (Ser428) Cell Signaling Cat# 2853, RRID:AB_2290281
Anti-Phospho-Akt (Ser473) (736E11) Cell Signaling Cat# 3787, RRID:AB_331170
Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(20G11)
Cell Signaling Cat# 4376, RRID:AB_331772
Anti-Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) Cell Signaling Cat# 4511, RRID:AB_2139682
Anti-Phospho-SAPK/JNK (Thr183/Tyr185) Cell Signaling Cat# 9251, RRID:AB_331659
Anti-NF-KappaB p65, phospho (Ser536) Cell Signaling Cat# 3033, RRID:AB_331284
Anti-RIPK1 Cell Signaling Cat# 3493, RRID:AB_2305314
Anti-Aurora A Cell Signaling Cat# 3092, RRID:AB_2061342
Anti-Bcl-xL Cell Signaling Cat# 2762, RRID:AB_10694844
Anti-MCL-1 Cell Signaling Cat# 4572, RRID:AB_2281980
Anti-Cyclin B1 Santa Cruz Cat# sc-752, RRID:AB_2072134
Anti-CDC25A Santa Cruz Cat# sc-7389, RRID:AB_627226
Anti-CDK1, phospho (Y15) Abcam CAT# ab133463
Anti-Phospho KAP-1 (S824) Bethyl Cat# A300-767A, RRID:AB_669740
Anti-NEK2 BD Biosciences Cat# 610593, RRID:AB_397933
Anti-HMMR Origene Cat# TA307117, RRID:AB_10620394
Anti-PLK1 Millipore Cat# 06-813, RRID:AB_310254
Anti-E-cadherin Cell Signaling Cat# 3195, RRID:AB_2291471
Anti-ZEB1 Santa Cruz Cat# sc-10572, RRID:AB_2273177
Anti-Fibronectin BD Biosciences Cat# 610077, RRID:AB_2105706
IRDye 680RD Goat anti-Mouse LI-COR Cat# 925-68070, RRID:AB_2651128
IRDye 800CW Goat anti-Rabbit LI-COR Cat# 925-32211, RRID:AB_2651127
HRP-conjugated swine anti-rabbit DAKO/Agilent Cat# P0217, RRID:AB_2728719
HRP-conjugated rabbit anti-mouse DAKO/Agilent Cat# P0260, RRID:AB_2636929
Alexa Fluor 647 goat anti-mouse Thermo Fisher Scientific Cat# A-21235, RRID:AB_2535804
Alexa Fluor 488 goat anti-rabbit Thermo Fisher Scientific Cat# A-11008, RRID:AB_143165
Alexa Fluor 488 goat anti-mouse Thermo Fisher Scientific Cat# A-11001; RRID:AB_2534069
Chemicals, Peptides, and Recombinant Proteins
Cisplatin Accord Healthcare Ltd Dutch drug database ZI# 15683354
Doxycycline Sigma Aldrich Cat. D9891
Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma Aldrich Cat. M2128
Halt Protease Inhibitor Cocktail Thermo Fisher Sci. Cat. 78425
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Halt Phosphatase Inhibitor Cocktail Thermo Fisher Sci. Cat. 78426
Mitomycin C Sigma Aldrich Cat. M4287
Propidium Iodide Sigma Aldrich Cat. P4170
RNaseH Thermo Fisher Sci. Cat. EN0201
Odyssey Blocking Buffer LI-COR Cat. 927-40000
Critical Commercial Assays
RNAeasy Kit QIAGEN Cat. 74104
HumanHT-12 v4 Expression BeadChip Kit Illumina N/A
Bradford Protein assay Thermo Fisher Sci. Cat. 23200
Deposited Data
Raw mRNA expression data This paper GEO: GSE103115
Growth rate inhibition (GR) metrics of breast cancer cell
lines
(Hafner et al., 2016) LINCS dataset #20268
Experimental Models: Cell Lines
MDA-MB-231 ATCC Cat# CRL-12532, RRID:CVCL_0062
MDA-MB-157 ATCC Cat# HTB-24, RRID:CVCL_0618
MDA-MB-468 ATCC Cat# HTB-132, RRID:CVCL_0419
BT549 ATCC Cat# HTB-122, RRID:CVCL_1092
HCC38 ATCC Cat# CRL-2314, RRID:CVCL_1267
HCC70 ATCC Cat# CRL-2315, RRID:CVCL_1270
HCC1806 ATCC Cat# CRL-2335, RRID:CVCL_125
HCC1937 ATCC Cat# CRL-2336, RRID:CVCL_0290
SUM149PT BIOIVT RRID:CVCL_3422
CAL120 DSMZ Cat# ACC-459, RRID:CVCL_1104
Hs578T ATCC Cat# CRL-7849, RRID:CVCL_0332
HEK293T ATCC Cat. CRL-3216; RRID:CVCL_0063
Recombinant DNA
pLenti CMV/TO GFP-MDC1 (779-2) Addgene CAT# 26285, RRID:Addgene_26285
Tet-pLKO-puro Addgene CAT# 21915, RRID:Addgene_21915
pLKO.1 puro Addgene CAT# 8453 RRID:Addgene_8453
pCMV-VSV-G Addgene CAT# 8454 RRID:Addgene_8454
pCMV-dR8.2 dvpr Addgene CAT# 8455 RRID:Addgene_8455
pLKO.1-MK2#1 This paper N/A
pLKO.1-MK2#2 This paper N/A
pLKO.1-G3BP2#1 This paper N/A
pLKO.1-G3BP2#2 This paper N/A
pLKO.1-SCR Heijink et al., 2015 N/A
pLKO.1-LUC Heijink et al., 2019 N/A
Software and Algorithms
GeneSpring GX software Agilent Technologies https://www.agilent.com/
FlowJo software (version 10) FlowJo https://www.flowjo.com/
MATLAB MathWorks https://www.mathworks.com/
Odyssey LI-COR https://www.licor.com/





growth rate inhibition (GR) calculator (Hafner et al., 2016) http://www.grcalculator.org/grtutorial/Home.html
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E-PAGE 8% Protein Gels, 48-well Invitrogen Cat. EP04808
iBlot Transfer Stack, nitrocellulose Invitrogen Cat. IB301001LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcel
A.T.M. van Vugt (m.vugt@umcg.nl). Plasmids generated in this study will be provided upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human TNBC cell lines MDA-MB-468, MDA-MB-157, MDA-MB-231, CAL120 and Hs578T, and HEK293T human embryonic kidney
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM). Hs578T were further supplemented with 10 mg/ml insulin.
HCC38, BT549, HCC70, HCC1806 and HCC1937 were grown in RPMI 1640 media. SUM-149PT cells were grown in Ham’s F12 me-
dia supplemented with 5 mg/ml insulin and 1 mg/ml hydrocortisone. All culture media were supplemented with 10% fetal calf serum
(FCS), 100 units/ml penicillin, and 100 mg/ml streptomycin. The cell lines were cultured at 37C in a humidified incubator supplied with
5% CO2. When indicated, cells were treated with cisplatin (Accord). If indicated, cells were treated with 1 mg/ml doxycycline.
METHOD DETAILS
Viral Infection
To obtain stable MDC-GFP-expressing HCC38, BT549, MDA-MB-231 and MDA-MB-157 cell lines, cells were infected with pLenti
CMV/TOGFP-MDC1 (779-2), which was a gift from Eric Campeau (Addgene plasmid # 26285). GFP-positive cells were subsequently
sorted into polyclonal cell lines using a Moflo cell sorter.
shRNAs against MK2 and G3BP2 or a scrambled sequence (SCR) were cloned into pLKO.1 vectors using the Age1 and
EcoR1 restriction sites. The hairpin targeting sequences that were used are: MK2#1 50-CCAGCACTCGATTGTTGTAAA-30, MK2#2
50-AGAAAGAGAAGCATCCGAAAT-30, G3BP2#1 50-GACTCTGACAACCGTAGAATA-30, G3BP2#2 50-GTGATGATCGCAGGGA
TATTA-30, SCR 50-CAACAAGATGAAGAGCACCAA-30 and luciferase (‘shLUC’), 50-AAGAGCTGTTTCTGAGGAGCC-30) (Heijink
et al., 2019). Lentiviral particles were produced as described previously (Heijink et al., 2015). In brief, HEK293T packaging cells
were transfected with 4 mg plasmid DNA in combination with the packaging plasmids VSV-G and DYPR. Virus-containing superna-
tant was harvested at 48 and 72 hours after transfection and filtered through a 0.45 mm syringe filter, and used to infect target cells in
three consecutive 12 hour periods.
MTT Assays
Cells were seeded in 96-well plates at 3,000 to 4,000 cells per well and treated with indicated concentrations of cisplatin. After 72
hours of treatment, methyl thiazol tetrazolium (MTT) was added to a final concentration of 0.5 mg/ml and cells were incubated for
four additional hours. Cells were then dissolved in DMSO and the produced formazan wasmeasured at 520 nmwith a Bio-Rad iMark
spectrometer. Growth rate inhibition (GR) metrics were calculated using a custom MATLAB script (Data S1), based on a previously
described R script (Hafner et al., 2016). Average growth rates for each cell line were calculated based on LINCS dataset #20268 (Haf-
ner et al., 2016).
Immunofluorescence Microscopy
Cells were left untreated or were irradiated with 10Gy using a Cesium137 source (CIS international/IBL 637 irradiator, dose rate:
0.01083 Gy/s). Three hours later, cells were fixed in 2% paraformaldehyde with 0.1% Triton X-100 in PBS for 30 minutes at room
temperature. Cells were permeabilized in 0.5% Triton X-100 in PBS for 10 minutes. To block nonspecific binding, cells were incu-
bated with PBS containing 0.05% Tween-20 and 4% BSA (Fraction V) (PBS-Tween-BSA) for 1 hour. Cells were incubated overnight
at 4C with mouse anti-RAD51 (GeneTex, GTX70230, 1:400) in PBS-Tween-BSA. Cells were extensively washed and incubated for
45 minutes with Alexa488-conjugated secondary antibodies. Images were acquired on a Leica DM-6000RXA fluorescence micro-
scope, equipped with Leica Application Suite software.
Low-Throughput Western Blotting
Knockdown efficiencies and the ubiquitination of FANCD2were analyzed by western blotting. Cells were lysed inMammalian Protein
Extraction Reagent (MPER, Thermo Scientific), supplemented with protease and phosphatase inhibitor mixtures (Thermo Scientific).e3 Cell Reports 28, 2345–2357.e1–e5, August 27, 2019
Forty micrograms of protein extract was used for separation by SDS/PAGE. Separated proteins were transferred to Polyvinylidene
fluoride (PVDF) membranes and blocked in 5% (wt/vol) BSA in Tris-buffered saline (TBS), with 0.05% Tween20. Immunodetection
was done with antibodies directed against FANCD2 (sc-20022, Santa Cruz), G3BP2 (A302-040A, Bethyl), phospho-MK2 (#3041,
Cell Signaling), E-cadherin (#3195, Cell Signaling), ZEB1 (sc-10572, Santa Cruz), Fibronectin (610077, BD Biosciences) and b-actin
(0869100, MP Biomedicals). Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (DAKO) were used for
enhanced chemiluminescence (Lumi-Light, Roche Diagnostics) on a Bio-Rad bioluminescence device, equipped with Quantity
One/ChemiDoc XRS software (Bio-Rad). Knockdown efficiency was quantified using Adobe Photoshop. To this end, Biorad SCN
files were exported into TIF files after which gray scale values were inverted. Mean intensity of a fixed-size rectangular marquee sur-
rounding bands was assessed. Mean intensity was corrected for mean local background, and related to action intensity which was
measured similarly. For G3BP2, shRNAs were designed to target all transcript variants. We assessed the bands at the indicated size,
which represent the long isoform of G3BP2, encoded bymRNA variants 1 and 2, which only differ in their 50 UTR. TheG3BP2 antibody
that we used (Bethyl-A302-040A) was raised against a 51 amino acid peptide of the long isoform, and detects a bandwith a predicted
molecular weight of 54 kDa of the long G3BP2 isoform.
RNA Expression Analysis by Microarray Analysis
Total RNAwas extracted fromMDA-MB-231, MDA-MB-157, HCC38 and BT549 cells after treatment with 2 mMcisplatin for 0, 24 and
72 hours using the RNAeasy Kit (QIAGEN). The Illumina whole-genome expression array HumanHT-12 v4.0 (Illumina) was used and
processed at the UMCGMedical Genetics department on a fee-for-service basis. Microarray data were obtained from two indepen-
dent biological replicates per time point. Data were normalized using percentile shift normalization using GeneSpring GX software
(Agilent Technologies). The cut-off for differential gene expression (DEG) was greater than 1.75-fold change and a p value less
than 0.05. Expression data can be found in the GEO repository under the accession number GSE103115.
Live Cell Microscopy
GFP-MDC1-expressing TNBC cells were seeded in 8-chambered cover glass plates (Lab-Tek-II, Nunc). 16 hours after plating, cells
were treated with 2 mM cisplatin for 24 hours. After media replacement, GFP and DIC images were obtained every 5 minutes over a
period of 16 hours on a DeltaVision Elitemicroscope, equippedwith a CoolSNAPHQ2 camera and a 20x immersion objective (U-APO
340, numerical aperture: 1.35) as described previously (Heijink et al., 2015). In the Z-plane, 6 images were acquired at 0.5-micron
interval. Image analysis was done using SoftWorX software (Applied Precision/GE Healthcare). The number of MDC1-foci before,
during and just after mitosis was scored.
Flow Cytometric Analysis
Cells were plated 24 hours prior to treatment with 2 or 20 mM cisplatin. Following treatment, cells were washed in PBS, trypsinized,
and fixed in ice-cold 70% ethanol. Cells were stained with anti-phospho-Ser139-histone-H2A.X (#9718, Cell Signaling) or anti-phos-
pho-histone-H3 (#9706, Cell Signaling) and subsequently stained with Alexa488-conjugated secondary antibodies, in combination
with propidium iodide/RNase treatment. Samples were measured on a FACSCalibur (Becton Dickinson) and data were analyzed us-
ing the FlowJo software. The level of cell death was measured as fractionated DNA (sub-G1).
Cells were synchronized at the G1/S transition using a 24-hour incubation with 2.5 mM thymidine. After extensive washing, cells
were released and harvested at indicated time points and subsequently fixed in ice-cold 70% ethanol.
High-Throughput Western Blotting
Cells were washed twice in PBS and lysed directly on the plate in Mammalian Protein Extraction Reagent (MPER, Thermo Scientific),
supplemented with protease inhibitor and phosphatases inhibitor mixture (Thermo Scientific). Cell lysates were normalized for pro-
tein content using the BCA protein assay (Pierce). Lysates were run on 48-well 8% pre-cast poly-acrylamide gels (E-PAGE, Invitro-
gen) and transferred using the iBlot gel transfer device onto nitrocellulose membranes (Invitrogen). Blots were blocked in Odyssey
Blocking Buffer (LiCOR Biosciences), incubated overnight with primary antibody at 4 degrees, stained with secondary antibodies
conjugated to an infrared dye for 1 hour at RT, and visualized using an Odyssey scanner (LiCOR Biosciences).
Most antibodies used in this study were purchased fromCell Signaling, including those targeting gH2AX (#9718), CDC25C (#4688),
p-CHK1-Ser345 (#2348), p-CHK2-Thr68 (#2197), p-MK2-Thr334 (#3041), p-ATR-Ser428 (#2853), p-AKT-Ser473 (#3787), p-ERK-
Thr202/Tyr204 (#4376), p-P38-Thr180/Tyr182 (#4511), p-JNK-Thr183/Tyr185 (#9251), p-NFkB p65-Ser536 (#3033), RIPK1
(#3493), Aurora A (#3092), Bcl-xL (#2762) and MCL1 (#4572). Antibodies against CyclinB1 (sc-752), FANCD2 (sc-20022) and
CDC25A (sc-7389) were purchased from Santa Cruz, antibodies against p-CDK1-Y15 (ab133463) and RPA32 (ab2175) from Abcam,
antibodies against p-KAP1-ser824 (A300-767A) and G3BP2 (A302-040A) from Bethyl, antibodies against NEK2 (610593) from BD
Bioscience, antibodies against HMMR (TA307117) from Origene, antibodies against b-actin (0869100) fromMPBiomedicals and an-
tibodies against PLK1 (06-813) were from Millipore.
For computational modeling, raw signals for each protein were quantified and background was subtracted using Li-COR Odyssey
software. For each gel, loading differences were corrected through normalization to b-actin signals. For gel-to-gel normalization,
samples were normalized using a reference sample, which was loaded on each gel. The reference sample for all signals was derived
from MCF-7 cells, lysed at 3 hours after irradiation (10Gy). For time-course plots, signal averages were calculated from biologicalCell Reports 28, 2345–2357.e1–e5, August 27, 2019 e4
duplicate experiments. The data were then plotted as a fold change to the lowest value that was measured of that particular signal
across all cell lines and treatments. Signaling plots for each individual metric were shaded in gray scale, with darkness reflecting
signal strength (Figures 2C, 2E and S6A). The background of each individual box is colored according to signaling profile: ‘sustained
increase’ in green, ‘late increase’ in red, ‘transient increase’ in yellow and ‘sustained decrease’ in blue. A signaling profile was as-
signed if the maximum signal of a time-course plot reachedR 33% of the maximum signal measured across all cell lines and treat-
ments. Plots are colored as ‘sustained increase’ or ‘sustained decrease’ when signal strength increased or decreases for at least six
subsequent time points, respectively. In case the fold changewas higher than two-fold increasewithin the last three time points, plots
are colored as ‘late increase’. Plots are colored as ‘transient increase’ when the difference between theminimumandmaximum value
wasR 2-fold and the maximum value is neighbored by ascending or descending values respectively.
Computational Data-Driven Modeling
Data-driven modeling and the application of partial-least-squares to biological data have been described in detail previously (Janes
and Yaffe, 2006). In PLS modeling, the goal is to use X (signals) to predict Y (responses) and to describe their covariance. The data
were divided into two matrices: E (a matrix containing the X variables) and F (a matrix containing the Y variables). In our study, the
dimensions of E are 176 3 25 signals (2 treatments x 4 cell lines x biological duplicate measurements x 11 time points) and the di-
mensions of F are 1763 6 (six cellular responses). Signal dynamics can be lost in PLS modeling due to uncoupling of temporal data.
Therefore, we quantified several aspects of each signaling trajectory of which the approach was similar to that used previously by
Janes et al. (2008). In the current study, all data were mean centered and unit variance scaled to non-dimensionalize the different
measurements. PLSR analyses were performed using the program SIMCA-P (Umetrics), using the combined dataset as provided
in Table S1. The PLS model was constructed using the following iterative formulas:
E1 = X t1pT1;E2 =E1  t2PT2; t2 =E1w1;Ei =Ei1  tipTi ; ti =Ei1wiF1 = Y b1t1qT1;F2 =F1  b2t2qT2 ;Fi = Fi1  bitiqTi
E represents the residual of the principal component, with score vector t, weight vector w, loading vector p, and T represents trans-
pose. F represents the residuals of the dependent principal component, with score vector t, loading vector q, and b represents the
inner relation between the independent and dependent principal components. Model predictions were made via cross-validation by
leaving out a random sample of 1/6th of the observations and predicting that 1/6th from the remaining 5/6th of the data. The process
was reiterated until each of the data were omitted and predicted. Model fitness was calculated using R2 and Q2, which were calcu-
lated as described previously (Gaudet et al., 2005). VIP scores were calculated as previously described (Janes et al., 2008). Meta-
variables that captured signal dynamics were calculated as 1) average, 2) area-under-the curve, 3) slope (between first time point
and last time point of time frame), 4) maximum slope (highest slope observed in time frame), 5) fold change (maximum value divided
by minimum value in time frame) and 6) dynamical range (maximum value minus lowest value in time frame). For Figure 6, the original
training model was extended with signaling and response data of MDA-MB-468, HCC1806 and HCC1143 cells. Signaling data were
included for five signals (pMK2, RPA, G3BP2, pKAP1 and BCL-xL), which were measured at 11 time points in response to treatment
with 20 mMcisplatin (5 signals x 3 cell linemodels x 2 biological replicatemeasurements x 11 time points x1 treatment = 330 additional
signal dimensions of ‘E’). In total, 4 responses (sub-G1, G1, S, G2/M) were measured (1 treatment x 3 cell lines x biological duplicate
measurements x 11 time points x 4 responses = 264 additional phenotype dimensions of ‘F’).
QUANTIFICATION AND STATISTICAL ANALYSIS
Information about statistical details can be found in the figure legends. Differences with p value < 0.05 were considered significant,
with * representing p < 0.05, ** representing p < 0.01, *** representing p < 0.001 and **** representing p < 0.0001. Throughout the
manuscript, graphs represent means, with error bars representing standard error of the means (SEM) or standard deviation (SD)
as indicated. P values were calculated using two-tailed Student’s t test. For RNA expression analysis, the cut-off for differential
gene expression (DEG) was a fold change greater than 1.75-fold, and a p value less than 0.05 as assessed using GeneSpring GX
software.
DATA AND CODE AVAILABILITY
ThemRNAexpression data generated during this study are available at theGEO repository under the accession number GSE103115.e5 Cell Reports 28, 2345–2357.e1–e5, August 27, 2019
